Company: DVAX
Filing Date: 2025-04-29
Form Type: DEFA14A
Source: 0000930413-25-001558
Chunk: 5

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-29
Form: DEFA14A
Chunk 5
---
,” “plan,” “potential,”
“seek,” “would” and similar expressions, or the negatives thereof, or they may use future dates. Forward-looking
statements made in this document include statements regarding expected contributions from newly appointed directors, expectations
regarding delivering value for our stockholders, our future growth, potential of our differentiated technology, timing of clinical
trials and expected results, market share and size of the market, expected product revenue, our business strategy and long-term
performance. Actual results may differ materially from those set forth in this communication due to the risks and uncertainties
inherent in our business, including, the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change,
risks relating to our ability to commercialize and supply HEPLISAV-B, and risks related to the implementation of our long-term
growth objectives, as well as other risks detailed in the “Risk Factors” section of our Annual Report on Form 10-K
for the financial year ended December 31, 2024 and any periodic filings made thereafter, as well as discussions of potential risks,
uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These forward-looking
statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we undertake no obligation
to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Information on Dynavax’s website at www.dynavax.com is not incorporated by reference in our current periodic reports with
the SEC.

Important Additional Information and Where to Find It

On April 17, 2025, the Company filed a definitive proxy statement
on Schedule 14A (the “Proxy Statement”) and form of accompanying GOLD proxy card with the U.S. Securities and Exchange
Commission (the “SEC”) in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company’s
director nominees and for other matters to be voted on. The Company may also file other relevant documents with the SEC regarding
its solicitation of proxies for the 2025 Annual Meeting. This communication is not a substitute for any proxy statement or other
document that the Company has filed or may file with the SEC in connection with any solicitation by the Company. STOCKHOLDERS OF
THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, ACCOMPANYING GOLD PROXY CARD AND OTHER RELEV